Compedica

About Compedica

Compedica Limited is a UK-based medical device company founded in 2010 by Jim Mellon, Jamie Gibson, and Daniel Blackman. The company focuses on developing solutions to prevent and treat Diabetic Foot Ulcers (DFUs). Operating in the UK and UAE, Compedica addresses the significant health and economic challenges posed by DFUs, a common complication of diabetes that can lead to infection and amputation. The company's primary product is the PulseFlowDF™, an FDA and CE-approved wearable therapy system. Marketed as the OptiPulse™ Active Therapy System, this prescription-only device integrates a plantar compression pump into a protective wearable. It is designed to enhance blood flow, relieve pressure from the wound area, and monitor patient compliance, all while allowing the user to remain mobile. This approach combines mobile offloading and blood flow stimulation to create an environment conducive to healing for patients at home. Compedica’s business model targets healthcare professionals and their patients, providing tools for DFU treatment protocols. The company’s leadership team includes founder Jim Mellon, an asset management specialist, and Chairman Jamie Gibson, who has a background in corporate finance and direct equity investments. The company has secured Series B funding and continues to focus on merging podiatry and vascular surgery principles with material science and mechanical engineering.